Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Non-radiographic axial spondyloarthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms Ability-3
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 30 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
    • 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
    • 24 Oct 2018 Results assessing the Adalimumab Concentration as predictor of of achievement of sustained remission and absence of flare in Patients with Non-Radiographic Axial Spondyloarthritis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top